This inventor holds 3 USPTO granted patents. Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharmaceuticals, Inc.. Active years: 2005-2008.
Company Filing History:
3 out of 1,560 
2 out of 278 
Years Active: 2005-2008
Title: Marlies Sproll: Innovator in Oncology
Introduction
Marlies Sproll is a prominent inventor based in Gauting, Germany. She has made significant contributions to the field of oncology through her innovative research and development of antibody-based therapies. With a total of 3 patents to her name, Sproll is recognized for her groundbreaking work in cancer treatment.
Latest Patents
One of her latest patents is titled "Antibodies specific for CD44v6." This invention focuses on antibodies that are specific for an epitope coded by the variant exon v6 of the CD44 gene. It includes nucleic acid molecules encoding these antibody proteins and methods for their production. Additionally, it provides pharmaceutical compositions that incorporate these antibody proteins, aimed at treating cancer. Another significant patent is "Cytotoxic CD44 antibody immunoconjugates," which relates to novel conjugates of CD44 antibodies with cytotoxic compounds. This invention also includes pharmaceutical compositions comprising these compounds and their application in tumor therapy.
Career Highlights
Marlies Sproll has worked with notable companies such as Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. Her experience in these organizations has contributed to her expertise in the development of innovative therapeutic solutions.
Collaborations
Throughout her career, Sproll has collaborated with esteemed colleagues, including Erik Patzelt and Karl-Heinz Heider. These partnerships have further enhanced her research and development efforts in the field of oncology.
Conclusion
Marlies Sproll is a distinguished inventor whose work in antibody development has the potential to revolutionize cancer treatment. Her contributions to the field are invaluable, and her ongoing research continues to inspire advancements in oncology.